Intex Andarine - Intex Pharma

Andarine, also known as S4, was first described in 2001 by researchers at the University of Tennessee. Developed by GTx Inc., it was aimed at treating muscle wasting and benign prostatic hypertrophy. It mimics the anabolic effects of testosterone but with reduced androgenic side effects, making it a preferred choice for athletes seeking muscle preservation without significant estrogenic or androgenic effects. Despite promising early studies, Andarine's development was halted, and it now circulates mainly as a research compound in the bodybuilding community.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Intex Andarine by Intex Pharma, consult with your doctor or healthcare professional.